APA (7th ed.) Citation

D, Y., S, K., H, T., Y, I., H, A., K, A., . . . H, E. (2024). ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)? Annals of surgical oncology, 31(7), 4702. https://doi.org/10.1245/s10434-024-15244-6

Chicago Style (17th ed.) Citation

D, Yamada, et al. "ASO Author Reflections: Which Was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?" Annals of Surgical Oncology 31, no. 7 (2024): 4702. https://doi.org/10.1245/s10434-024-15244-6.

MLA (9th ed.) Citation

D, Yamada, et al. "ASO Author Reflections: Which Was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?" Annals of Surgical Oncology, vol. 31, no. 7, 2024, p. 4702, https://doi.org/10.1245/s10434-024-15244-6.